These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2561387)

  • 21. Low-molecular-weight heparins and angiogenesis.
    Norrby K
    APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC; Cohen M; Montalescot G
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
    Brewer D
    J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low molecular weight heparins better than unfractionated heparin in unstable coronary artery disease? Unstable angina pectoris/non-Q wave infarction a partly outpatient clinic condition?
    Kauw FH; Cleophas TJ; Kalmansohn RB
    Int J Clin Pharmacol Ther; 1998 Jul; 36(7):392-7. PubMed ID: 9707355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of low molecular weight heparin in the prevention of postoperative deep venous thrombosis. Our experience in 88 cases].
    Verardi S; Cortese F; Baroni B; Boffo V; Casciani CU
    G Chir; 1989 Nov; 10(11):674-8. PubMed ID: 2562010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook].
    Fiessinger JN
    Bull Acad Natl Med; 1997 May; 181(5):875-83; discussion 883-5. PubMed ID: 9312362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic use of low molecular weight heparins: the knowledge to date as applied to therapy.
    Hull RD; Pineo GF
    Semin Thromb Hemost; 1993; 19 Suppl 1():111-5. PubMed ID: 8395712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
    Fareed J; Haas S; Sasahar A
    Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects.
    Doutremepuich C; Guyot M; Lalanne MC; Deharo E; Walenga JM; Fareed J
    Thromb Res; 1989 Aug; 55(4):419-26. PubMed ID: 2554524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-molecular-weight heparin.
    Wolf H
    Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low molecular weight heparin(s).
    Barrowcliffe TW
    Br J Haematol; 1995 May; 90(1):1-7. PubMed ID: 7786769
    [No Abstract]   [Full Text] [Related]  

  • 37. Low molecular weight heparins. An objective overview.
    Hoppensteadt D; Walenga JM; Fareed J
    Drugs Aging; 1992; 2(5):406-22. PubMed ID: 1327312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H. activity in thrombosis? (Part II).
    Doutremepuich F; Lalanne MC; Slimani M; Doutremepuich C
    Thromb Res; 1992 May; 66(4):445-9. PubMed ID: 1329259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of an intervention on the prescription and biological surveillance of low-molecular weight heparins in medicine].
    Fiessinger JN; Chatellier G
    Presse Med; 1996 Nov; 25(36):1777-80. PubMed ID: 8991025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Low-molecular weight heparins].
    Montloin A
    Rev Infirm; 1990 Mar; 40(5):49-52. PubMed ID: 1965236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.